Hims & Hers rebounds with key partnerships and launches, achieving 111% YoY revenue growth. Learn more about HIMS stock here.

The momentum is now with Lilly. Visible Alpha, a data firm, expects its sales of obesity drugs to overtake Novo’s by 2027 ...

The chart I drew up below showcases just how expensive Hims products were, before this morning’s partnership, when compared to the competition. Hims can sell Wegovy to its existing customer base ...

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of medicines it covers for reimbursement, but shares of the drugmaker still fell ...

Novo’s has fallen by as much (see chart 2). Lilly’s edge rests on a more effective drug, better execution, some keener pricing and a stronger pipeline. Zepbound and Wegovy belong to a class of ...

A 4.1 magnitude earthquake rattled eastern Tennessee and was felt all through the Southeastern states. 'The Big Weekend Show' panelists discuss President Donald Trump's new announcement.

The stock of Hims & Hers Health Inc. (HIMS) fell more than 4% in after-hours trading after the telehealth company issued ...

Novo Nordisk (NYSE:NVO) shares dropped 5% in early trading on Monday after Eli Lilly (NYSE:LLY) released new trial data showing its weight loss drug, Zepbound, delivered stronger results than Wegovy.

The S&P 500 rose in choppy trading after the Federal Reserve signaled that the risks for an economic slowdown and higher ...

Veru Inc (VERU) reports positive Phase 2B study results for Novosarm ... 3:20 pm Paci After losing some value lately, a hammer chart pattern has been formed for Veru (VERU), indicating that ...

Weight loss drugs are getting more popular, even for teenagers and pre-teens -- but while many doctors have reported ...

When considering a weight loss medication — or any medication — it’s normal to wonder when the effects will kick in.